Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647107 | 0.88 | JMJD6 (0.46) | JMJD6 | |
| SCHEMBL30593721 | 0.80 | XDH (0.59) | — | |
| SCHEMBL1647090 | 0.80 | XDH (0.59) | — | |
| SCHEMBL3716982 | 0.76 | THRA (0.43) | — | |
| SCHEMBL1647158 | 0.76 | HPGDS (0.43) | — | |
| SCHEMBL31464233 | 0.74 | KDM4E (0.46) | KDM5BKDM4CJMJD6KDM4EKDM6B | |
| SCHEMBL29082871 | 0.74 | KDM4E (0.46) | KDM5BKDM4CJMJD6KDM4EKDM6B | |
| SCHEMBL1647684 | 0.73 | KMO (0.49) | KMOKDM5BKDM4CKDM4AKDM4E | |
| SCHEMBL3710951 | 0.73 | XDH (0.56) | KDM4E | |
| SCHEMBL10819459 | 0.73 | SMN1; SMN2 (0.43) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | claimed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | claimed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | claimed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | claimed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | KMO 138/4885HCAR3 1788/4885KDM5A 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.